Dr. Risch explains in detail why they're wrong:
1) Trials on already-hospitalized patients were used to say it won't work if given early.
2) Trials on relatively young populations yielding no statistical differences were used to say it doesn't work on vulnerable patients.
How is it that ZERO RCTs were conducted on vulnerable patients well before potential hospitalization was necessary? And yet Pfizer "miraculously" comes up with a drug with exact same protease inhibitor as HCQ and was smart enough to perform RCTs on vulnerable patients within 5 days of symptom onset.
I read the entire paper. It's indisputable HCQ+ works. And Dr. George Fareed, formerly of Harvard and UCLA medical schools, 100% concurs.